background
treatment
ipilimumab
fulli
human
antibodi
approv
treatment
advanc
melanoma
associ
immunerel
advers
event
ira
coliti
gastrointestin
ira
gi
ira
skin
rash
manag
treatment
guidelin
nevertheless
predict
biomark
help
identifi
patient
like
develop
ira
could
enhanc
manag
toxic
method
identifi
candid
predict
biomark
associ
gi
ira
gene
express
profil
perform
whole
blood
sampl
advanc
melanoma
patient
baselin
week
start
ipilimumab
treatment
two
phase
ii
clinic
trial
overal
patient
develop
grade
higher
grade
gi
ira
cours
treatment
repeat
measur
analysi
varianc
anova
use
evalu
differ
mean
express
level
gi
ira
nogi
ira
group
patient
three
time
point
result
baselin
sampl
probe
set
show
differenti
mean
express
fold
p
gi
ira
nogi
ira
group
probe
set
belong
three
function
categori
immun
system
cell
cycl
intracellular
traffick
chang
gene
express
time
also
character
gi
ira
group
probe
set
fold
chang
express
baselin
week
first
ipilimumab
dose
respect
particular
ontreat
express
increas
two
neutrophilactiv
marker
close
associ
gi
ira
suggest
possibl
role
neutrophil
ipilimumabassoci
gi
ira
addit
express
sever
immunoglobulin
gene
increas
time
greater
increas
patient
grade
gi
ira
conclus
gene
express
profil
peripher
blood
sampl
earli
cours
treatment
ipilimumab
result
identif
set
potenti
biomark
associ
occurr
gi
ira
howev
low
sensit
biomark
use
alon
predict
patient
develop
gi
ira
investig
biomark
larger
patient
cohort
warrant
ipilimumab
fulli
human
monoclon
antibodi
block
cytotox
tlymphocyt
approv
us
food
drug
administr
fda
sever
regulatori
agenc
treatment
advanc
metastat
melanoma
mm
efficaci
ipilimumab
demonstr
number
phase
ii
two
phase
iii
clinic
trial
mm
patient
signific
prolong
overal
surviv
report
treatment
ipilimumab
associ
spectrum
ae
immun
mediat
call
immunerel
advers
event
ira
gastrointestin
gi
ira
diarrhea
coliti
among
common
ipilimumabassoci
ira
case
onset
gi
ira
occur
second
third
dose
ipilimumab
ira
manag
accord
establish
treatment
guidelin
previou
report
examin
colon
biopsi
safetyfocus
clinic
trial
reveal
abund
focal
neutrophil
cryptiti
neutrophil
infiltr
lamina
propria
affect
tissu
patient
experienc
gi
ira
although
administr
high
dose
steroid
often
lead
success
safe
manag
major
ira
identif
biomark
may
predict
soon
start
treatment
ira
might
improv
patient
care
context
peripher
blood
biomark
would
prefer
sinc
collect
peripher
blood
less
invas
colon
biopsi
understand
underli
caus
ipilimumabassoci
gi
ira
identifi
potenti
predict
biomark
gene
express
profil
perform
whole
blood
sampl
collect
metastat
melanoma
patient
ipilimumab
treatment
two
phase
ii
clinic
trial
number
cell
cycleand
immunerel
gene
found
higher
express
baselin
postbaselin
patient
experienc
gi
ira
particular
increas
express
neutrophil
activ
marker
found
associ
occurr
gi
ira
addit
greater
increas
express
immunoglobulinrel
gene
detect
week
patient
gi
ira
without
result
consist
understand
mechan
underli
ipilimumabassoci
gi
ira
provid
list
potenti
peripher
blood
biomark
earli
predict
ira
multicent
phase
ii
clinic
trial
enrol
previouslytr
untreat
patient
stage
iii
unresect
iv
melanoma
random
arm
receiv
intraven
infus
either
mgkg
ipilimumab
everi
week
induct
phase
trial
previous
treat
patient
stage
iii
unresect
iv
melanoma
n
receiv
openlabel
ipilimumab
mgkg
everi
week
four
dose
random
receiv
concomit
blind
prophylact
oral
budesonid
mgd
gradual
taper
week
placebo
exclus
criteria
includ
use
immunosuppress
treatment
includ
corticosteroid
patient
stabl
dose
hormon
replac
therapi
exempt
cyclosporin
mycophenol
mofetil
cellcept
w
well
chemotherapi
radiat
within
week
prior
first
ipilimumab
dose
complet
studi
design
patient
characterist
endpoint
report
trial
describ
elsewher
gene
express
profil
twenti
patient
treat
ipilimumab
monotherapi
mgml
use
confirm
data
set
present
analysi
studi
conduct
accord
ethic
principl
origin
current
declar
helsinki
consist
intern
confer
harmon
good
clinic
practic
ethic
principl
underli
european
union
direct
unit
state
code
feder
regul
titl
part
protocol
patient
inform
consent
form
receiv
appropri
approv
institut
review
board
independ
ethic
committe
prior
studi
initi
particip
patient
legal
accept
repres
gave
written
inform
consent
biomarkerfocus
studi
safeti
evalu
use
nation
cancer
institut
common
terminolog
criteria
advers
event
base
advers
event
ae
physic
examin
clinic
laboratori
assess
drugrel
gastrointestin
ae
consist
immunemedi
event
intrins
biolog
activ
ipilimumab
examin
report
advers
event
record
base
meddra
system
organ
class
prefer
term
clinic
activ
ca
defin
confirm
complet
respons
confirm
partial
respons
stabl
diseas
end
earlier
week
date
first
ipilimumab
dose
complet
descript
ira
ca
evalu
trial
report
elsewher
neutrophil
quantifi
compon
standard
hematolog
panel
absolut
neutrophil
count
avail
variou
time
point
patient
whole
blood
sampl
gene
express
profil
collect
prior
first
dose
ipilimumab
baselin
week
first
ipilimumab
dose
total
rna
extract
whole
blood
sampl
use
paxgen
blood
rna
mdx
kit
biorobot
univers
system
qiagen
valencia
ca
purifi
rneasi
minelut
cleanup
kit
use
qiacub
qiagen
valencia
ca
rna
concentr
measur
nanodrop
spectrophotomet
rna
integr
evalu
agil
bioanalyz
agil
technolog
santa
clara
ca
complementari
dna
prepar
hybrid
plate
follow
manufactur
protocol
affymetrix
santa
clara
ca
affymetrix
raw
data
cel
file
normal
robust
multiarray
analysi
rma
algorithm
obtain
wwwbioconductororg
version
appropri
affymetrix
control
probe
set
examin
ensur
qualiti
control
cdna
synthesi
hybrid
step
princip
compon
analysi
pca
subsequ
perform
detect
outlier
sampl
singl
sampl
account
high
degre
variat
data
sampl
remov
outlier
antilog
rma
valu
use
subsequ
statist
analys
combin
data
studi
noncontrol
probe
set
maximum
express
level
rma
normal
less
probe
set
low
express
level
across
sampl
exclud
analysi
gene
express
data
analys
gi
ira
statu
avail
treat
patient
gene
express
data
avail
patient
patient
express
data
avail
least
time
point
patient
includ
subsequ
analys
patient
classifi
nogi
ira
group
includ
patient
worstgrad
gi
ira
total
patient
grade
greater
grade
gi
ira
classifi
gi
ira
group
nogi
ira
gi
ira
group
respect
baselin
express
data
avail
patient
week
data
avail
patient
week
data
avail
patient
repeat
measur
analysi
varianc
anova
model
fit
partek
genom
suit
www
partekcom
antilog
normal
express
level
depend
variabl
explanatori
variabl
includ
patient
time
point
within
patient
factor
binari
gi
ira
statu
timebystatu
interact
gi
ira
observ
treatment
arm
rel
small
sampl
size
individu
trial
data
patient
two
trial
combin
increas
statist
power
detect
associ
statist
infer
base
model
focus
two
hypothesi
test
test
null
hypothesi
mean
gene
express
averag
time
two
gi
ira
statu
group
test
null
hypothesi
mean
gene
express
averag
gi
ira
statu
three
time
point
uncorrect
p
valu
use
cutoff
select
probe
set
mean
express
differ
comparison
group
qvalu
packag
r
statist
comput
environ
http
wwwrprojectorg
use
estim
fals
discoveri
rate
fdr
express
select
gene
confirm
quantit
polymeras
chain
reaction
qpcr
describ
previous
use
predesign
probe
function
interpret
differenti
express
gene
comput
use
ingenu
pathway
analysi
ipa
softwar
ingenu
system
describ
previous
express
noncontrol
probe
set
analyz
individu
gene
associ
gi
ira
statu
grade
vs
select
assess
differ
mean
pretreat
express
gi
nogi
ira
group
two
select
criteria
appli
p
valu
hypothesi
test
compar
gi
nogi
ira
group
minimum
mean
pretreat
express
ratio
test
p
valu
threshold
correspond
estim
fdr
set
probe
set
repres
uniqu
gene
met
criteria
addit
file
tabl
list
includ
number
immunerel
gene
cell
cycleand
proliferationassoci
gene
gene
involv
intracellular
vesicl
traffick
picalm
molecul
report
either
present
neutrophil
regul
function
identifi
earli
ontreat
predictor
ipilimumabassoci
gi
ira
postbaselin
express
level
noncontrol
probe
set
compar
gi
ira
nogi
ira
group
thirti
five
probe
set
identifi
mean
express
ratio
least
week
sampl
respect
p
valu
fdr
hypothesi
test
compar
gi
nogi
ira
group
sinc
ipilimumabassoci
gi
ira
occur
second
third
dose
ipilimumab
probe
set
differenti
express
week
particular
interest
might
serv
earli
predictor
help
identifi
patient
experi
gi
ira
second
dose
given
week
addit
file
tabl
probe
set
exhibit
largest
differenti
express
correspond
neutrophilspecif
marker
glycosylphosphatidylinositol
gpi
link
cell
surfac
molecul
differ
baselin
express
patient
gi
nogi
ira
group
howev
significantli
higher
express
found
one
dose
ipilimumab
gi
ira
group
fold
higher
gi
ira
group
nogi
ira
group
week
p
addit
increas
mean
express
baselin
week
much
greater
gi
ira
group
nogi
ira
group
addit
file
tabl
mean
increas
express
associ
clinic
activ
ca
ipilimumab
p
figur
express
level
sampl
confirm
quantit
pcr
show
statist
signific
differ
gi
ira
nogi
ira
group
unadjust
p
chang
time
unadjust
p
data
suggest
potenti
earli
predictor
gi
ira
increas
gene
express
might
also
consequ
treatment
ipilimumab
independ
clinic
activ
sinc
neutrophil
surfac
marker
examin
relationship
pbanc
express
level
mean
pbanc
increas
gradual
ipilimumab
treatment
largest
appar
increas
occur
week
patient
highergrad
gi
ira
figur
predictor
gi
ira
associ
ipilimumab
treatment
pbanc
express
week
larg
interindividu
variabl
consider
higher
valu
patient
rest
figur
seven
patient
high
level
express
rmanorm
express
level
week
grade
gi
ira
cours
treatment
suggest
high
specif
biomark
threshold
howev
mani
patient
grade
gi
ira
normal
express
level
week
suggest
low
sensit
biomark
predict
gi
ira
addit
file
figur
week
postbaselin
sampl
high
express
level
found
gi
ira
nogi
ira
group
mani
patient
grade
gi
ira
alreadi
discontinu
treatment
time
point
data
week
might
bias
inform
dropout
also
explor
time
onset
gi
ira
individu
patient
establish
valu
express
earli
predictor
patient
grade
gi
ira
match
gene
express
data
week
patient
report
first
gi
ira
day
day
nomin
date
blood
sampl
collect
wherea
patient
gi
ira
report
date
figur
four
highest
valu
express
detect
patient
report
first
grade
gi
ira
day
day
blood
sampl
collect
receiv
first
dose
ipilimumab
note
one
patient
high
express
week
report
grade
gi
ira
day
figur
mark
gray
shade
circl
progress
grade
ultim
led
fatal
gi
perfor
data
suggest
although
consider
increas
gene
express
close
associ
onset
gi
ira
earli
increas
might
also
predict
gi
ira
could
develop
much
later
howev
sinc
low
sensit
biomark
could
identifi
futur
gi
ira
associ
express
neutrophilassoci
gene
glycoprotein
express
neutrophil
neutrophil
metamyelocyt
myelocyt
blood
cell
therefor
specif
search
neutrophilassoci
gene
better
understand
implic
granulocyt
subtyp
earli
predictor
gi
ira
includ
gene
encod
granuleassoci
protein
olfactomedin
azurocidin
lactoferrin
ltf
cathelicidin
camp
myeloperoxidas
mpo
bactericidalperm
increas
protein
bpi
defensin
neutrophil
elastas
elan
cathepsin
g
ctsg
mediat
neutrophil
adhes
endotheli
cell
facilit
transmigr
tissu
genechip
includ
probe
set
mani
gene
addit
file
tabl
although
appar
greater
express
gene
found
sampl
high
level
express
figur
express
significantli
linearli
correl
week
r
p
probe
set
probe
set
consequ
pattern
mean
gene
express
time
similar
figur
fiftyeight
probe
set
identifi
least
chang
baselin
week
sampl
respect
p
fdr
test
time
effect
express
addit
file
tabl
perform
pathway
analysi
use
ipa
softwar
differenti
express
probe
set
sinc
size
gene
set
amen
analysi
top
biolog
process
exhibit
chang
ipilimumab
treatment
includ
pathway
cell
prolifer
metabol
immunerel
pathway
signal
signal
b
cell
develop
figur
exhibit
largest
chang
baselin
time
point
immunoglobulinrel
gene
domin
list
includ
show
signific
increas
express
week
baselin
slight
increas
express
gene
alreadi
appar
week
sampl
suggest
earli
onset
antibodi
respons
much
larger
expans
later
time
point
addit
file
tabl
figur
notabl
increas
express
gene
time
promin
gi
ira
group
nogi
ira
group
correspond
increas
bcell
marker
gene
suggest
cell
type
respons
increas
express
immunoglobulin
gene
may
bcell
laterstag
blineag
cell
plasma
cell
whole
blood
sampl
clinic
studi
independ
analyz
use
statist
model
studi
patient
treat
ipilimumab
monotherapi
mgkg
everi
week
dose
mean
express
ratio
compar
gi
ira
nogi
ira
group
week
respect
signific
differ
baselin
gi
ira
group
mean
fold
chang
baselin
week
respect
contrast
nogi
ira
group
chang
neglig
respect
express
chang
similar
seen
two
studi
observ
granuleassoci
gene
signific
chang
baselin
week
gi
ira
group
nogi
ira
group
addit
file
tabl
treatment
ipilimumab
shown
prolong
overal
surviv
advanc
melanoma
patient
phase
trial
gastrointestin
ira
diarrhea
coliti
among
common
sometim
sever
form
advers
event
associ
ipilimumab
advers
event
current
manag
follow
treatment
guidelin
howev
identif
predict
biomark
import
may
enhanc
manag
toxic
improv
patient
care
present
studi
undertaken
identifi
biomark
peripher
blood
previou
report
trial
colon
biopsi
collect
chang
colon
mucosa
follow
onset
diarrhea
appear
sever
observ
prespecifi
biopsi
follow
first
dose
ipilimumab
histopatholog
examin
biopsi
reveal
activ
coliti
mark
neutrophil
infiltr
lamina
propria
strike
characterist
affect
tissu
biopsi
foci
neutrophil
cryptiti
crypt
abscess
glandular
destruct
eros
mucos
surfac
also
appar
earli
start
treatment
patient
present
gi
ira
symptom
howev
collect
colon
biopsi
consid
invas
procedur
therefor
peripheralblood
surrog
marker
would
prefer
gi
ira
onset
commonli
observ
second
third
dose
ipilimumab
gene
express
profil
use
pretreat
blood
sampl
identifi
immunerel
gene
higher
baselin
express
patient
develop
gi
ira
includ
interleukin
natur
killer
might
interest
gene
list
cytokin
report
play
central
role
acut
flare
inflammatori
bowel
diseas
well
autoimmun
diseas
rheumatoid
arthriti
select
express
activ
cytotox
natur
killer
nk
cell
potenti
effect
activ
innat
immun
system
monocyt
macrophag
secret
chemotact
factor
tumor
necrosi
factoralpha
number
studi
current
studi
although
treatmentinduc
chang
express
signific
pathway
analysi
found
signal
one
top
pathway
chang
treatment
figur
increas
express
neutrophilassoci
gene
notic
shortli
start
treatment
particular
significantli
greater
mean
express
neutrophil
surfac
marker
detect
subset
patient
experienc
gi
ira
grade
greater
neutrophil
granulocyt
abund
type
white
blood
cell
mammal
form
essenti
part
innat
immun
system
acut
phase
inflamm
particularli
result
bacteri
infect
environment
exposur
cancer
neutrophil
among
firstrespond
inflammatori
cell
migrat
toward
site
inflamm
transmigr
blood
vessel
interstiti
tissu
follow
chemic
signal
leukotrien
process
call
chemotaxi
uniqu
marker
neutrophil
upregul
upon
neutrophil
activ
acut
inflammatori
respons
toward
stimuli
bacteri
infect
signific
increas
mean
express
marker
detect
patient
experienc
moder
sever
gi
ira
independ
clinic
respons
ipilimumab
inde
seven
patient
highest
express
level
normal
express
level
week
alreadi
would
experi
gi
ira
within
day
three
week
time
point
current
gi
ira
ipilimumab
treatment
manag
accord
treatment
guidelin
cessat
ipilimumab
combin
treatment
corticosteroid
blockad
one
earlier
ipilimumab
monotherapi
trial
guidelin
yet
fulli
place
trial
two
patient
die
sever
gi
ira
intestin
perfor
one
patient
provid
baselin
week
blood
sampl
gene
express
analysi
increas
express
baselin
week
appar
almost
day
onset
first
gi
ira
episod
suggest
earli
predict
valu
biomark
sever
gi
ira
shown
recogn
endotheli
cell
junction
molecul
platelet
endotheli
cell
adhes
contribut
interact
neutrophil
endotheli
cell
mediat
transendotheli
migrat
context
inflammatori
cell
recruit
anoth
marker
express
activ
neutrophil
also
show
consist
increas
mean
express
baselin
week
first
ipilimumab
dose
greater
increas
gi
ira
group
wherea
mostli
activ
marker
neutrophil
mediat
adher
activ
neutrophil
hematopoiet
cell
nk
cell
cytokineactiv
endothelium
suggest
play
role
immunemedi
diseas
intestin
elev
express
report
cell
lamina
propria
small
intestin
patient
celiac
diseas
larg
intestin
inflammatori
bowel
diseas
ibd
appar
associ
neutrophil
count
gene
express
ipilimumabassoci
gi
ira
led
us
search
neutrophilassoci
gene
microarray
data
degranul
process
neutrophil
releas
assort
protein
mpo
elan
extracellular
space
gene
includ
neutrophil
modul
report
chaussabel
et
al
although
trend
greater
express
gene
found
sampl
highest
level
express
figur
statist
signific
linear
correl
express
data
shown
fact
mean
express
gene
week
sampl
lower
baselin
addit
file
tabl
left
panel
greatest
increas
detect
patient
suggest
express
might
repress
earli
neutrophil
activ
event
convers
signific
increas
mean
express
gene
observ
week
addit
file
tabl
support
notion
degranul
process
follow
neutrophil
activ
event
observ
also
confirm
anoth
data
set
independ
ipilimumab
clinic
trial
higher
mean
express
found
gi
ira
group
addit
list
potenti
earli
predictor
gi
ira
share
number
common
element
set
gene
report
confer
resist
intraven
corticosteroid
therapi
children
ulcer
coliti
gene
share
two
studi
includ
bpi
clc
hp
studi
postbaselin
sampl
collect
three
day
start
corticosteroid
treatment
signific
differenti
express
gene
steroidresist
sensit
patient
studi
earliest
postbaselin
blood
sampl
collect
week
first
dose
ipilimumab
major
chang
gene
express
occur
within
time
period
suggest
might
possibl
detect
predict
profil
even
earlier
time
within
period
event
chang
tend
preced
signific
increas
number
peripher
neutrophil
suggest
prolifer
neutrophil
occur
activ
event
chang
gene
express
may
serv
sensit
biomark
increas
peripher
blood
absolut
neutrophil
count
pbanc
anoth
interest
find
analysi
consider
increas
number
express
immunoglobulinrel
gene
week
first
dose
ipilimumab
patient
gi
ira
accord
previou
report
inhibitori
effect
immunoglobulin
cytokin
product
plasma
cell
inhibitori
effect
cell
mediat
cell
help
b
cell
antibodi
product
blockad
ipilimumab
like
reduc
inhibit
healthi
peopl
humor
respons
enter
flora
maintain
homeostasi
dysregul
homeostasi
manifest
increas
antibodi
level
select
enter
microorgan
characterist
gastrointestin
disord
ibd
acut
gi
inflamm
ie
diverticulitisinfect
previou
report
trial
ipilimumab
found
induc
antibodi
respons
select
enter
flora
pseudomona
saccharomyc
cerevisia
cbir
flagellin
howev
strong
associ
posit
level
antibodi
respons
toward
specif
bacteria
gi
ira
observ
although
gene
express
profil
could
provid
inform
regard
specif
induc
antibodi
still
indic
patient
experienc
gi
ira
immunoglobulin
product
machineri
turn
absenc
infect
extern
pathogen
respons
may
well
due
gener
antibodi
self
antigen
express
intestin
flora
identifi
earli
chang
gene
express
patient
treat
ipilimumab
patient
might
predict
incid
later
gi
ira
gene
express
chang
togeth
prior
histopatholog
examin
affect
tissu
point
import
role
neutrophil
onset
gi
ira
patient
high
express
week
specif
biomark
grade
gi
ira
patient
event
display
express
level
certain
threshold
normal
express
level
howev
low
sensit
biomark
express
alon
use
predict
patient
develop
gi
ira
may
occur
patient
low
express
earliest
ontreat
sampl
collect
week
first
ipilimumab
dose
therefor
clear
much
increas
express
preced
onset
gi
ira
studi
identifi
potenti
biomark
ipilimumab
toxic
biolog
plausibl
howev
valid
larger
control
trial
need
assess
potenti
clinic
util
addit
file
tabl
list
potenti
predict
earlypredict
biomark
probe
set
greater
mean
baselin
express
blood
sampl
patient
grade
gi
ira
patient
grade
gi
ira
highlight
column
mean
express
ratio
postbaselin
sampl
well
p
valu
test
differ
baselin
mean
express
two
gi
ira
group
also
shown
b
probe
set
mean
express
ratio
least
comparison
gi
ira
nogi
ira
group
week
highlight
column
mean
express
ratio
time
point
well
p
valu
test
differ
week
mean
express
two
gi
ira
group
also
shown
mean
express
ratio
posit
valu
give
mean
express
gi
ira
group
mean
express
nogi
ira
group
neg
valu
give
neg
mean
express
nogi
ira
group
mean
express
gi
ira
group
tabl
list
potenti
pharmacodynam
biomark
probe
set
chang
mean
gene
express
baselin
week
left
panel
week
right
panel
top
probe
set
shown
gi
ira
group
highlight
column
fold
chang
nogi
ira
group
well
p
valu
test
differ
baselin
postbaselin
express
also
shown
mean
fold
chang
posit
valu
give
mean
postbaselin
express
baselin
express
neg
valu
give
neg
mean
baselin
express
postbaselin
express
tabl
granuleassoci
gene
express
profil
mean
express
ratio
compar
gi
ira
nogi
ira
group
granuleassoci
gene
time
point
p
valu
test
differ
mean
express
two
gi
ira
group
averag
three
time
point
also
shown
b
mean
fold
chang
baselin
bl
gi
ira
nogi
ira
group
granuleassoci
gene
p
valu
test
differ
mean
express
among
three
time
point
averag
two
group
shown
definit
mean
express
ratio
mean
fold
chang
see
legend
tabl
respect
tabl
complet
list
potenti
pharmacodynam
biomark
probe
set
mean
chang
gene
express
baselin
week
gi
ira
group
highlight
column
fold
chang
nogi
ira
group
well
p
valu
test
differ
baselin
postbaselin
express
also
shown
mean
fold
chang
posit
valu
give
mean
postbaselin
express
baselin
express
neg
valu
give
neg
mean
baselin
express
postbaselin
express
tabl
granuleassoci
gene
express
profil
mean
express
ratio
compar
gi
ira
nogi
ira
group
granuleassoci
gene
time
point
p
valu
test
differ
mean
express
two
gi
ira
group
averag
three
time
point
also
shown
b
mean
fold
chang
baselin
bl
gi
ira
nogi
ira
group
granuleassoci
gene
p
valu
test
differ
mean
express
among
three
time
point
averag
two
group
shown
mean
express
ratio
posit
valu
give
mean
express
gi
ira
group
mean
express
nogi
ira
group
neg
valu
give
neg
mean
express
nogi
ira
group
mean
express
gi
ira
group
mean
fold
chang
posit
valu
give
mean
postbaselin
express
baselin
express
neg
valu
give
neg
mean
baselin
express
postbaselin
express
addit
file
figur
roc
curv
express
week
predictor
gi
ira
plot
includ
patient
known
gi
ira
statu
express
valu
author
contribut
db
zt
sdc
mjk
design
two
biomark
focus
clinic
trial
lw
bh
lp
perform
pcr
assay
prepar
rna
affymetrix
microarray
analysi
mjk
assist
data
analysi
interpret
vf
sdc
zt
rj
perform
data
analysi
interpret
prepar
manuscript
author
read
approv
final
manuscript
